Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 228-237

  Ghatalia, Pooja ^a   Morgan, Charity J ^b   Je, Youjin ^b   Nguyen, Paul L ^c   Trinh, Quoc Dien ^c   Choueiri, Toni K ^c   Sonpavde, Guru ^a  

^a University of Alabama at Birmingham   (United States)

^b Kyung Hee University   (South Korea)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Approved; Congestive heart failure; Meta analysis; Tyrosine kinase inhibitors; Vascular endothelial growth factor receptor

Indexed keywords

AXITINIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INTERFERON; IRINOTECAN; LEVOLEUCOVORIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PREDNISONE; SORAFENIB; SUNITINIB; VANDETANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ACUTE HEART FAILURE; BREAST CANCER; BREAST METASTASIS; CARDIOMYOPATHY; CASTRATION RESISTANT PROSTATE CANCER; CHEMOEMBOLIZATION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE DURATION; GASTROINTESTINAL STROMAL TUMOR; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOKINESIA; KIDNEY CARCINOMA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CELL CARCINOMA; MELANOMA; META ANALYSIS; METASTATIC COLORECTAL CANCER; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTRICULAR HYPOKINESIA; ANTAGONISTS AND INHIBITORS; COMPLICATION; NEOPLASMS; ODDS RATIO; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ANTINEOPLASTIC AGENTS; HEART FAILURE; HUMANS; NEOPLASMS; ODDS RATIO; PROTEIN KINASE INHIBITORS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK;

EID: 84926101029     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.008     Document Type: Review

References (39)

1. Richards C.J., Je Y., Schutz F.A., Heng D.Y., Dallabrida S.M., Moslehi J.J., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011, 29:3450-3456. (Official Journal of the American Society of Clinical Oncology).
2. Choueiri T.K., Mayer E.L., Je Y., Rosenberg J.E., Nguyen P.L., Azzi G.R., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29:632-638. (Official Journal of the American Society of Clinical Oncology).
3. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012, 30:871-877. (Official Journal of the American Society of Clinical Oncology).
4. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
5. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62:e1-e34.
6. Schwarzer G. Meta-analysis with R. R package version 2.3-0 2013, 〈http://CRANR-projectorg/package=metaY
7. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft 2010, 36(3):1-48.
8. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
9. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
10. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
11. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304:2154-2160.
12. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
13. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
14. Paz-Ares L.G., Biesma B., Heigener D., von Pawel J., Eisen T., Bennouna J., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30:3084-3092.
15. Gonçalves A., Gilabert M., François E., Dahan L., Perrier H., Lamy R., et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012, 23:2799-2805.
16. Kindler H.L., Ioka T., Richel D.J., Bennouna J., Létourneau R., Okusaka T., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12:256-262.
17. Rugo H.S., Stopeck A.T., Joy A.A., Chan S., Verma S., Lluch A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29:2459-2465.
18. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
19. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513.
20. Barrios C.H., Liu M.C., Lee S.C., Vanlemmens L., Ferrero J.M., Tabei T., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
21. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30:921-929.
22. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
23. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M., Lim R., Roman L., Shparyk Y., et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013, 31:1341-1347.
24. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
25. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
26. van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
27. Crown J.P., Diéras V., Staroslawska E., Yardley D.A., Bachelot T., Davidson N., et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013, 31:2870-2878.
28. Michaelson M.D., Oudard S., Ou Y., Sengeløv L., Saad F., Houede N., et al Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014, 32:76-82.
29. Gridelli C., Novello S., Zilembo N., Foa P., Favaretto A., De Marinis F., et al. Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). J Clin Oncol 2012, 30. (suppl; abstr 7550).
30. de Boer R.H., Arrieta Ó Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29:1067-1074.
31. Lencioni R., Llovet J.M., Han G., Tak W., Yang J., Leberreet M., et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012, 30.. (suppl 4; abstr LBA154).
32. Flaherty K.T., Lee S.J., Zhao F., Schuchter L.M., Flaherty L., Kefford R., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013, 31:373-379.
33. Ranpura V., Hapani S., Chuang J., Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010, 49:287-297.
34. Deuse T., Peter C., Fedak P.W., Doyle T., Reichenspurner H., Zimmermann W.H., et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009, 120:S247-S254.
35. Qi W.X., Shen Z., Tang L.N., Yao Y. Congestive heart failure risk in 554 cancer patients treated with VEGFR-TKIs: a systematic review and 555 meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014, 78:748-762.
36. Van den Akker N.M., Winkel L.C., Nisancioglu M.H., Maas S., Wisse L.J., Armulik A., et al. PDGF-B signaling is important for murine cardiac development: its role in developing atrioventricular valves, coronaries, and cardiac innervation. Dev Dyn 2008, 237:494-503.
37. Cheng H., Kari G., Dicker A.P., Rodeck U., Koch W.J., Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 2011, 109:1401-1409.
38. Cooper H., Hedges L. The handbook of research synthesis 1994, Russell Sage, New York, NY.
39. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13:1-10.